# Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Source: https://onco.cc/trials/nct06110572/  
OnCo record `nct06110572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of carboplatin, atezolizumab and etoposide in lung cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.

## Summary

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation is a phase 1/2, interventional study registered as NCT06110572 by Vanderbilt-Ingram Cancer Center, with a registry enrolment figure of 18 participants, started 2024-04-24 and due to reach its primary completion in 2027-06-30. Interventions recorded: Carboplatin; Atezolizumab; Etoposide; Total Body Irradiation; Hypofractionated Radiation Therapy; Magnetic Resonance Imaging. Conditions listed: Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer. Primary outcome: Rates of treatment-related adverse events; Progression-free survival. Lung eligibility wording from the registry: "* Histologically documented or cytologically confirmed diagnosis of extensive stage small-celllung cancer with evaluable disease per RECIST v1". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: TESSERACT
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06110572
- Phase: 1/2
- Setting: (TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)
- Sponsor: Vanderbilt-Ingram Cancer Center
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT06110572: https://clinicaltrials.gov/study/NCT06110572

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06110572.json